Reapplix

Reapplix has established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process.

Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative , evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else.

Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the 2018 EY Entrepreneur of the Year Award in the life science category.

Every Wound is Personal

Mission

Drawing on the person’s power to heal so they can get back to living their best life.

A Closer Look

In July 2018, Reapplix moved forward, based on the strong clinical results of the recent independent RCT, and has formed Reapplix Inc. based in Texas to bring the 3C Patch® System onto the US market.

Developing innovative solutions needed to help patients and society while also creating successful business is in the DNA of inventor Niels Erik Holm who is also known for inventing several successful medical devices (Insulin Infusion Set, Feeding tubes, Novolet Pen, Vivostat System, Seroma Set) and for generating over 60 patents. The NovoLet pen has sold over 750 million units.

Reapplix’s co-founders Niels Erik Holm and Rasmus Lundquist are both experienced and successful entrepreneurs driven to bring their proven value-based healthcare solution onto the market. Rasmus Lundquist, Reapplix’s Chief Scientific Officer, co-founded RAM Biotech Aps in 2001 prior to joining Reapplix and has a M.Sc. in biology and immunology from Copenhagen University and a graduate certificate in Bio Design from Stanford University.

Leadership

Kira Rupprecht

Chief Executive Officer

Commitment to Evidence

Clinical Data

In Vitro Data

3C Patch

3C Patch with Dr. James McGuire

Personalized Wound Healing

Diabetic foot ulcers have a debilitating impact on patients. Despite numerous treatment options, about 60% of all patients experience a wound that does not heal. If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound. For about 20% of patients, treatment ends in amputation within one year.

At Reapplix, we have established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Using just a small sample of the patient’s blood – nothing else – the 3C Patch® System separates, coagulates and compacts the blood components into a solid patch. The result is a single 3C Patch® comprising a concentration of proteins, active cells and growth factors.
Each 3C Patch® takes about 20 minutes to produce and is applied directly to the wound at point-of-care. One of few evidence-based wound treatments, the 3C Patch® is clinically proven to significantly accelerate wound healing of hard-to-heal diabetic foot ulcers. The outcome is a cost-effective, personalized wound treatment that draws on each patient’s unique ability to help their own healing process.
Every wound is personal.

SPECIALTIES

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!